Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial.
| Title: | Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. |
|---|---|
| Authors: | Ching THW; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Grazioplene R; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Bohner C; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Kichuk SA; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; DePalmer G; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; D'Amico E; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Eilbott J; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Jankovsky A; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Burke M; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Hokanson J; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Martins B; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Witherow C; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Patel P; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Amoroso L; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Schaer H; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Pittenger C; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.; Department of Psychology, Yale University, New Haven, CT, United States.; Center for Brain and Mind Health, Yale University School of Medicine, New Haven, CT, United States.; Child Study Center, Yale University School of Medicine, New Haven, CT, United States.; Kelmendi B; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States. |
| Source: | Frontiers in psychiatry [Front Psychiatry] 2023 Apr 25; Vol. 14, pp. 1178529. Date of Electronic Publication: 2023 Apr 25 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101545006 Publication Model: eCollection Cited Medium: Print ISSN: 1664-0640 (Print) Linking ISSN: 16640640 NLM ISO Abbreviation: Front Psychiatry Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Switzerland : Frontiers Research Foundation, 2010- |
| Abstract: | Background: Psilocybin may help treat obsessive-compulsive disorder (OCD). To date, only one open-label study of psilocybin for OCD exists, necessitating further investigation with a randomized controlled design. The neural correlates of psilocybin's effects on OCD have also not been studied.; Objectives: This first-of-its-kind trial aims to evaluate the feasibility, safety, and tolerability of psilocybin in the treatment of OCD, provide preliminary evidence on the effects of psilocybin on OCD symptoms, and elucidate neural mechanisms that may mediate psilocybin's effects on OCD.; Design: We use a randomized (1:1), double-blind, placebo-controlled, non-crossover design to examine the clinical and neural effects of either a single dose of oral psilocybin (0.25 mg/kg) or active placebo-control agent (250 mg of niacin) on OCD symptoms.; Methods and Analysis: We are enrolling 30 adult participants at a single site in Connecticut, USA who have failed at least one trial of standard care treatment (medication/psychotherapy) for OCD. All participants will also receive unstructured, non-directive psychological support during visits. Aside from safety, primary outcomes include OCD symptoms over the past 24 h, assessed by the Acute Yale-Brown Obsessive-Compulsive Scale and Visual Analog Scale ratings. These are collected by blinded, independent raters at baseline and the primary endpoint of 48 h post-dosing. Total follow-up is 12 weeks post-dosing. Resting state neuroimaging data will be collected at baseline and primary endpoint. Participants randomized to placebo will be offered the chance to return for an open-label dose of 0.25 mg/kg.; Ethics Statement: All participants will be required to provide written informed consent. The trial (protocol v. 5.2) was approved by the institutional review board (HIC #2000020355) and registered with ClinicalTrials.gov (NCT03356483).; Discussion: This study may represent an advance in our ability to treat refractory OCD, and pave the way for future studies of neurobiological mechanisms of OCD that may respond to psilocybin.; (Copyright © 2023 Ching, Grazioplene, Bohner, Kichuk, DePalmer, D’Amico, Eilbott, Jankovsky, Burke, Hokanson, Martins, Witherow, Patel, Amoroso, Schaer, Pittenger and Kelmendi.) |
| Competing Interests: | The authors declare the following conflict of interests. TC serves as a continuing faculty member in the Psychedelic-Assisted Therapy Training Program offered by Integrative Psychiatry Institute (IPI), and consults for Transcend Therapeutics. CP serves/has served as a consultant for Biohaven, Teva, Lundbeck, Brainsway, Ceruvia Lifesciences, Transcend Therapeutics, Nobilis Therapeutics, and Freedom Biotech, receives royalties and/or honoraria from Oxford University Press and Elsevier, and has filed a patent on the use of neurofeedback in the treatment of anxiety, which is not relevant to the current work. BK is co-founder and Chief Scientific Advisor for Transcend Therapeutics and has consulted for Ceruvia Lifesciences and Lobe Sciences. CP and BK have filed a patent on the use of psilocybin in the treatment of obsessive–compulsive disorder (#US17/466,111). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| References: | Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001765. (PMID: 18253995); Account Res. 2001;8(4):309-29. (PMID: 12481796); Perspect Psychol Sci. 2010 May;5(3):219-32. (PMID: 24839457); J Psychiatr Ment Health Nurs. 2011 Oct;18(8):744-50. (PMID: 21896118); Int Clin Psychopharmacol. 2013 Jul;28(4):200-5. (PMID: 23587985); Behav Res Ther. 2005 Nov;43(11):1527-42. (PMID: 16299894); J Psychopharmacol. 2008 Aug;22(6):621-32. (PMID: 18593735); J Cogn Neurosci. 2013 Sep;25(9):1397-405. (PMID: 23879877); J Subst Abuse. 1990;2(2):217-35. (PMID: 2136111); JAMA Psychiatry. 2021 May 1;78(5):481-489. (PMID: 33146667); J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57. (PMID: 9881538); Front Psychiatry. 2023 Mar 01;14:1088896. (PMID: 36937731); CNS Spectr. 2022 Jul 11;:1-11. (PMID: 35811423); Eur Neuropsychopharmacol. 2014 Mar;24(3):342-56. (PMID: 24444771); J Neurol Neurosurg Psychiatry. 2022 Sep 20;:. (PMID: 36127157); J Pain Symptom Manage. 2008 Apr;35(4):356-64. (PMID: 18222629); J Anxiety Disord. 2021 Jun;81:102407. (PMID: 33915506); Psychiatry Res. 1989 May;28(2):193-213. (PMID: 2748771); J Obsessive Compuls Relat Disord. 2020 Jan;24:100498. (PMID: 32140386); J Clin Psychiatry. 2016 May;77(5):e605-11. (PMID: 27249090); J Pers Soc Psychol. 1994 Dec;67(6):1063-78. (PMID: 7815302); Expert Opin Drug Saf. 2022 Jun;21(6):833-840. (PMID: 35225143); Psychopharmacology (Berl). 2022 Nov;239(11):3447-3460. (PMID: 34477887); Neuroimage. 2019 Aug 1;196:207-215. (PMID: 30965131); Behav Res Ther. 2000 Apr;38(4):347-72. (PMID: 10761280); Int J Neuropsychopharmacol. 2002 Jun;5(2):181-91. (PMID: 12135542); Arch Gen Psychiatry. 1989 Nov;46(11):1006-11. (PMID: 2684084); Clin Psychol Rev. 2015 Aug;40:156-69. (PMID: 26117062); Depress Anxiety. 2010 May;27(5):470-5. (PMID: 20455248); Biol Psychiatry. 2012 Dec 1;72(11):964-70. (PMID: 22784486); Psychol Assess. 2002 Dec;14(4):485-96. (PMID: 12501574); Front Neuroinform. 2023 Apr 05;17:1104508. (PMID: 37090033); J Psychopharmacol. 2011 Nov;25(11):1434-52. (PMID: 20855349); CNS Drugs. 2013 May;27(5):367-83. (PMID: 23580175); Am J Psychiatry. 1987 Sep;144(9):1239-40. (PMID: 3631327); N Engl J Med. 2022 Nov 3;387(18):1637-1648. (PMID: 36322843); Psychopharmacology (Berl). 2006 Aug;187(3):268-83; discussion 284-92. (PMID: 16826400); World Psychiatry. 2013 Jun;12(2):137-48. (PMID: 23737423); Br J Psychiatry. 1979 Apr;134:382-9. (PMID: 444788); Curr Psychiatry Rep. 2012 Jun;14(3):211-9. (PMID: 22527872); Psychiatry (Edgmont). 2007 Jul;4(7):28-37. (PMID: 20526405); Compr Psychiatry. 2021 Apr;106:152223. (PMID: 33618297); JAMA Psychiatry. 2013 Jun;70(6):608-18; quiz 554. (PMID: 23740049); CNS Spectr. 2013 Feb;18(1):21-33. (PMID: 23279901); Am J Psychiatry. 1997 Jul;154(7):1037-8. (PMID: 9210762); Acta Psychiatr Scand. 2021 Feb;143(2):101-118. (PMID: 33125716); J Clin Psychiatry. 2006 Nov;67(11):1735-40. (PMID: 17196053); J Psychopharmacol. 2016 Dec;30(12):1259-1267. (PMID: 27852960); Am J Psychiatry. 2007 Jul;164(7 Suppl):5-53. (PMID: 17849776); CNS Drugs. 2022 Jan;36(1):17-30. (PMID: 34791625); Eur Addict Res. 2005;11(1):22-31. (PMID: 15608468); Psychiatry Res. 2022 Jun;312:114567. (PMID: 35490573); Br J Psychiatry. 2012 Mar;200(3):238-44. (PMID: 22282432); Int Clin Psychopharmacol. 1996 Jun;11 Suppl 3:89-95. (PMID: 8923116); Exp Brain Res. 2013 Aug;228(4):481-91. (PMID: 23727882); J Sci Study Relig. 2012 Dec;51(4):721-737. (PMID: 23316089); J Pers Soc Psychol. 1989 Feb;56(2):199-208. (PMID: 2926623); Psychiatry Res. 2015 May 30;227(1):104-13. (PMID: 25937054); J Psychoactive Drugs. 2014 Nov-Dec;46(5):393-5. (PMID: 25364991); Psychopharmacology (Berl). 2004 Mar;172(2):145-56. (PMID: 14615876); J Psychopharmacol. 2016 Dec;30(12):1279-1295. (PMID: 27856683); Behav Res Ther. 1988;26(2):169-77. (PMID: 3365207); Arch Gen Psychiatry. 1989 Nov;46(11):1012-6. (PMID: 2510699); Depress Anxiety. 2013 Aug;30(8):716-22. (PMID: 23532944); Depress Anxiety. 2018 Jun;35(6):502-514. (PMID: 29451967); Int J Methods Psychiatr Res. 2012 Sep;21(3):169-84. (PMID: 22865617); Behav Res Ther. 2008 Aug;46(8):895-904. (PMID: 18514616); Biol Psychiatry. 2014 Apr 15;75(8):606-14. (PMID: 24099506); Mol Psychiatry. 2010 Jan;15(1):53-63. (PMID: 18725912); Neuropsychopharmacology. 2013 Nov;38(12):2475-83. (PMID: 23783065); Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2138-43. (PMID: 22308440); Aust N Z J Psychiatry. 2013 Feb;47(2):121-41. (PMID: 23125399) |
| Grant Information: | K23 MH122777 United States MH NIMH NIH HHS |
| Contributed Indexing: | Keywords: adult psychiatry; mental health; neuroimaging; obsessive–compulsive disorder; psilocybin; psychedelic; psychological support |
| Molecular Sequence: | ClinicalTrials.gov NCT03356483 |
| Entry Date(s): | Date Created: 20230514 Latest Revision: 20240927 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10166878 |
| DOI: | 10.3389/fpsyt.2023.1178529 |
| PMID: | 37181888 |
| Database: | MEDLINE |
Journal Article